us indic began modestli higher extend open gain session momentum past day continu
close broadli firmer crude gold advanc within technolog stock rule
assum coverag outperform rate target price
assum coverag made chang rate target price estim time
assum coverag outperform rate target price
assum coverag adob system made chang rate target price estim
contempl chang balanc growth profit rais estim lower tp
action/ev report result gross book vs cs gross profit vs cs
adj ebitda vs cs manag provid guidanc gross travel book
growth revenu gross profit growth fx-neutral basi adj ep
rais ep estim
invest thesi cite aim maintain certain roi goal book manag offer lower-than-expect
room night gross book growth expect even easier comparison trade-off/benefit lower
growth higher margin profit dollar redeploy appear long-term move
chang product offer pure hotels-onli transact proposit presum intermod
travel servic essenti replic tradit agenc put togeth form all-in packag ad flight
attract etc experi maintain outperform rate even price target adjust modestli lower
vs prior said expect share range-bound near term investor adjust prospect
chang travel shopper lifetim valu amidst bigger pictur aforement new product develop cycl
present consum expans offer captur greater share total travel dollar
estim chang result project revenu adj ebitda respect
valuat dcf-base price target contempl wacc termin growth decreas
risk includ competit on-line travel compani peer market de-lever
assum coverag outperform rate target price
assum coverag made chang rate target price estim
analyst disclosur credit suiss seek busi compani cover research
report result investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest
pbm head leav becom ceo dplo reiter pbm save outlook
ingeniorx ceo brian griffin resign becom dplo ceo chairman announc today brian griffin
ceo ingeniorx new pbm subsidiari resign compani mr griffin leav good term
becom diplomat pharmaci chief execut offic chairman board director effect
june quick convers manag compani note mr griffin alway desir ceo
role move becom ceo anoth compani understand
ingeniorx lead divis conduct extern search ingeniorx ceo deepti jain current
ingeniorx lead ingeniorx ms jain directli respons develop oper plan
compani ms jain join vice-president anthem pharmaci servic promot senior
vice-president anthem pharmaci solut prior join ms jain serv cigna pharmaci cfo
health plan divis medco health solut ms jain consider compani conduct
extern search fill ingeniorx ceo role
oper impact pbm timelin save outlook reiter ingeniorx remain track fulli
oper transit schedul begin compani reiter target gener
greater bln annual gross save
recent weak buy oppti reiter outperform share price level trade prior
releas despit report strong share trade ep estimate reflect
benefit new pbm effect see signific upsid share next month
assum coverag outperform rate target price
assum coverag made chang rate target price estim time
assum coverag outperform rate target price
assum coverag
made chang rate target price estim time
assum coverag neutral rate target price
assum coverag workday made chang rate target price estim time
first take neutral posit
neutral posit print view print overal solid beat top bottom line increas
full year outlook howev believ market expect modest beat expect nois result
market calibr wp new report convent consolid worldpay/vantiv busi new account
standard believ complic y/i compar
result first quarter vantiv worldpay oper combin compani worldpay beat con top
bottom line estim revenu vs guidanc cs/con estim
worldpay ebitda margin came vs cs/con estim adj ep came
vs guidanc cs/con estim
guidanc updat worldpay slightli rais lower upper end revenu guidanc
vs cs/con estim ep guidanc vs
cs/con estim
guidanc worldpay guid revenu rang adj ep
confer call worldpay host confer call discuss result today
receiv product pleas specifi credit suiss contact email call
symantec report result market close today thursday may expect press releas shortli
et follow confer call manag et call detail
expect upon market close expect press releas contain financial/oper highlight
guidanc consolid financi inform cfo commentari key non-gaap item like
organ perform segment defer revenu fx-adjust guidanc supplement inform detail
financi disclosur manag prepar remark
view setup follow disappoint result enterpris revenu miss expect
total revenu guid consensu think expect like suffici reset embed
realist deferr rate mix physical/virtu product therefor look in-lin result
guidanc think guidanc like key focal point investor announc durat
adjust enterpris bill use guid symc like guid revenu segment level
well opm ep
messag listen think four key messag investor like focus addit color
around enterpris bill durat health coat refresh extent virtual product adopt enterpris
margin potenti headwind aris wss/pki divestitur extent competit headwind face
endpoint market
assum coverag outperform rate target price
assum coverag shopifi made chang rate target price estim time
overal straightforward quarter unravel move piec lower estim target price
event meli report result gmv vs cs revenu gross bill vs
cs/con adj ep vs cs adjust price target vs
prior maintain outperform rate adj ep estim vs prior lower
ep estim
invest case chang account shortfal op profit lot digest overal
conclus result fairli straightforward import take-away us item purchas
per activ buyer continu grow call prior quarter primari justif
manag team decis continu spend custom acquisit even assum elev
market spend level go-forward basi remain comfort acquir meli share pullback gmv
estim beyond show greater upward bia post versu prior result price target edg
lower vs prior work latest currenc move maintain outperform rate base
follow factor take rate rise current next year street number low
credit compani variou product in-market option meli increas take rate on-platform
chang estim gmv revenu adj ep estim
valuat end dcf-deriv target use wacc termin growth rate
greater-than-expect macroeconom headwind brazil risk estim
receiv product pleas specifi credit suiss contact email call
price dynam slightli better april new vs use spread narrow
track consum price index cpi bureau labor statist new vs use vehicl proxi
vehicl price good direct indic use unit comp time april gap improv first
time sinc april use price start declin new continu declin use
encourag see spread start narrow await may data quarter to-dat trend would seem
support current comp expect neg mid-singl digit rang past improv encourag
along easier comparison low rel valuat help set past earli part year show insid
key driver stock use unit comp gross profit growth stock reflect
improv either
detail use price decreas base cpi april vs march new car price declin higher rate
last month use vehicl cpi apr vs feb point to-dat vs
new vehicl price april vs vs feb point
date vs overal new/us price spread better april bp vs bp march though still
point bp to-dat vs bp continu expect price issu prove transitori
stock data difficult comparison suggest comp still weak/neg estim stock
seem emb ntm pe stock chart updat insid
assum coverag outperform rate target price
assum coverag ultim softwar ulti made chang rate target price
estim time
assum coverag neutral rate target price
assum coverag inc
made chang rate target price estim time
press report suggest kkr could bid bln evhc
kkr reportedli consid bln bid wed new york report kkr consid buy-out evhc
could top billion articl say trump administr roll back limit lbo kkr
could take leverag transact secur financ would put leverag deal
cautiou report around evhc well-known strateg review think worth consid
would impli takeout price
scenario take report face valu takeout price assum total purchas price evhc bln
report would impli equiti valu bln deduct bln net debt use fulli load share count
mln takeout price per share roughli would impli premium wednesday close price
scenario assum fee takeout price assum total price bln includ fee
price fee bln would impli equiti portion would bln takeout price roughli
per share premium wed close
scenario assum bln transact fee takeout price provid level sensit around
recent articl assum final scenario transact price bln use transact price
assum fee includ mln price fee would bln otherwis use
assumpt takeout price per share would impli premium wednesday
view takeout price written previous think deal possibl
rang analysi assum leverag transact report accur evhc suitor may
will increas leverag rang somewhat higher transact price could doabl without
significantli dilut return sponsor rel previou analysi
receiv product pleas specifi credit suiss contact email call
assum coverag outperform rate target price
assum coverag inc made chang rate target price estim time
focu shift commerci execut follow recent andexxa approv lower estim
doubl launch stori earn mostli line expect initi bevyxxa
sale oper expens bump collabor revenu drive less anticip loss last week
andexxa approv fda behind us focu earn confer call compani plan
success execut roll andexxa bevyxxa maintain target price outperform rate
ep estim chang main
risk view poor commerci execut andexxa bevyxxa us well regulatori
delay andexxa eu
updat model includ lower revenu rais opex launch consid
bevyxxa andexxa initi stage launch andexxa launch limit due inventori limit
compani get fda approv manufactur process earli next year temper
expect product also adjust sg assumpt accordingli await next month
present better appreci potenti compani third wholli own asset cerdulatinib ad
revenu product model
assum coverag outperform rate target price
assum coverag cornerston on-demand inc
made chang rate target price estim time
solid quarter debt paydown focu
post slight solid ec pm sale report adj ep beat consensu
cse beat driven higher sale ec pm off-set
weather impact higher plant mainten refin servic continu expect gener strong
guid anticip predominantli use reduc debt expect pay
least view releas neutral core busi grow well debt pay seem
immin may concern margin ec
strong top-line growth weather mainten drag ec pm post strong quarter sale
driven higher demand sodium silic contribut sovitec acquisit fx ec grew top-line
pass-through higher cost refin servic zeolyst jv sale increas driven strong demand
growth emiss control ec ebitda growth larg driven volum emiss control
partial off-set advers weather higher yr/yr plant schedul mainten refin servic
question call provid updat timelin capac expans within ec pm
ii updat thermodrop visibl favor region regul iii region price trend ec iv
region demand trend zeolit silica catalyst refin servic outlook discuss contract renew
regener servic vi see raw materi price increas think vii
nt plan restructur debt capit deploy opportun potenti
assum coverag outperform rate target price
assum coverag alarm com made chang rate target price estim
time
receiv product pleas specifi credit suiss contact email call
assum coverag neutral rate target price
assum coverag mindbodi inc mb
made chang rate target price estim time
perman ceo remov overhang today dplo name brian griffin perman ceo effect june griffin
replac former interim ceo jeff park remain member dplo board director bod follow
retir co-found phil hagerman announc jan join dplo extens pbm industri
experi includ recent name ceo ingeniorx new pbm subsidiari three year
presid commerci specialti busi divis year lead pbm medco later
acquir express script esrx outperform also join compani bod chairman current cfo
atul kavthekar remain interim ceo formal assum new role
share rebound appoint respect industri veteran well-receiv investor
bring search hagerman replac close reiter compani recent initi lt pbm
strategi accord manag team desir becom public compani ceo
transit understand although initi surpris interim ceo jeff park resign see recent
note manag meet dplo race boston encourag wealth industri
experi broadli evolv strateg vision compet new manag extens pbm
experi view dplo better posit expand specialti pharmaci unit profit
assum coverag outperform rate target price
assum coverag made chang rate target price estim time
assum coverag neutral rate target price
assum coverag workiva made chang rate target price estim time
oper par guid elus rais estim lower target price
ep miss consensu ep estim weaker revenu
off-set slightli better profit factor line primarili drove miss lower ep
reflect miss lower tp lower view await highli
revenu light improv profit report revenu increas estim note re-
segment make segment revenu estim less relevant/compar global solut revenu excl
interseg elimin increas global product revenu excl interseg elimin
drop previous disclos custom loss gross margin increas bp better plan
bp admin expens higher bp y/i net bp ebitda margin improv slightli
forecast bp gener cash flow million vs million cash reserv stand
share may ebb lot hing call commentari share may come pressur despit rel
line oper experi absenc updat guidanc re-segment question remain
potenti relief on-going headwind core domest segment continu seen pressur
key variabl mind acquisit halyard health ip busi littl instil greater confid nt
turnaround leav meaning lever view downsid warrant given on-going
competit challeng amidst like lacklust fundament demand reiter under-perform rate risk
receiv product pleas specifi credit suiss contact email call
fire twelv cylind rais target price
engin solari one greatest success stori oilfield servic industri cycl probabl
sever plan drive save wellsit effici across wellsit buffer storag leapt
market share lead ramp manufactur capac year oper everi major unconvent
basin drawback ebitda margin might see much near-term expans cse
highest corpor ebitda margin sector high revenu growth next two year happen
question high-class one
top end manag note plan reinvest opportun drive wellsit save effici
noth fit high bar invest return found sever mechan return cash
sharehold compani goe cash flow posit earli ebitda margin cash flow gener
signific kingfish transload facil oper current anchor busier expect
new construct cadenc unit per month would expect unit move
end drive well revenu growth year see signific pickup use
pack five three differ custom quarter compound demand
tach ebitda goe compani call reset price
rate addit full quarter contribut railtronix compani caution ebitda margin north
conserv margin drive roughli unchang ebitda estim take target
price maintain outperform rate target price dcf-base wacc termin
growth rate equal treasuri risk nam recoveri oil price
assum coverag neutral rate target price
assum coverag made chang rate target price estim time
food inflat stay posit april bare
cs view recent commentari cover compani demonstr continu diverg food retail versu
wholesal report inflat impact retail see flattish trend foodservic distributor see inflat
today food cpi releas highlight weak trend retail y/i growth come
stack improv third consecut month remain neg
categori protein inflat acceler april dairi slightli less deflationari
sequenti produc notori volatil dip deflationari territori cereals/bakeri loos proxi
center store groceri flat
histor compani correl figur figur full report present histor cpi correl ident
store sale chang gross margin kr given high concentr produc sale total
focu categori compani
inject consensu impli bcfd loosen weather-adjust s/d balanc
storag inject line consensu inventori rose bcf spot consensu bcf top
forecast rang bcf inject last week inject last year bcf five-year averag
bcf inject inventori increas bcf narrow deficit vs last year five-year averag bcf
weather last week warmer last year line averag last week weather warmer
year-ago week line averag sinc septemb weather colder last
year averag respect heat degre day remain ahead us
last week withdraw impli weather-adjust s/d balanc loosen bcfd last month
estim weather-adjust s/d oversuppli bcfd vs last year undersuppli bcfd vs
five-year averag storag bcf last year natur ga price support bcfd yoy refil
demand order return normal end inject season level preliminarili forecast storag refil
lesser novemb bcf year-ago averag head winter
forecast bcf inject next week forecast bcf inject report next week compar
last year bcf inject five-year averag bcf inject
gassi ps discount long-term natur ga price impli valuat modestli attract vs
long-dat futur curv normal forecast top pick
apc vnom top ga pick
receiv product pleas specifi credit suiss contact email call
investor sentiment remain poor innov like upsid
macro outlook reason investor sentiment poor concern around drug price continu percol
believ fundament macro backdrop us pharma sector remain favor tax cut job act tcja
help drive repatri fund oversea ultim lead increas activ space
boost growth outlook larg cap compani increas investor interest compani cap size
could potenti target addit fund dividend growth share repurchas also boost overal outlook
sector investor perspect see regulatori environ remain gener favor provid
rapid path market product bring real innov deliv innov remain paramount
compani compet deliv upsid increasingli challeng payer environ
move top pick continu favor follow releas impress data last
month oncolog meet see top pick believ compani solidifi leadership
posit commerci lucr lung cancer market expect strong uptak keytruda monotherapi
combin alimta nonsmal cell lung cancer nsclc patient posit data
could expand use keytruda nsclc move number two univers driven
robust pharma busi includ asset darzalex imbruvica xarelto think exceed current
expect remain outperform-r base valuat confid strength core aesthet
busi believ critic pipelin deliv posit data off-set pressur gener competit
multipl product
multipl near-term catalyst smid cap see top pick smid cap follow posit phase data
aaaai andexxa approv expect product bevyxxa start make
impact corpor strategi perspect learn plan split two compani
come week see pivot data fomx initi phase data
receiv product pleas specifi credit suiss contact email call
hh secretari preview trump drug initi congression testimoni today
today hh secretari azar testifi subcommitte labor human servic educ
relat agenc review budget request hh among thing mr azar ask comment
presid trump friday speech quick take
hh secretari highlight four problem focu presid trump speech respons
question mr azar said friday speech focu four key problems/area administr might revers
current incent favor high list price ensur govern proper date program
tool ensur negoti best price ensur adequ competit drug market
relat roll-out gener altern drug biosimilar respect patent game speed approv
process reduc pocket expens beneficiari hh secretari ask provid
detail declin ahead presid speech tomorrow
high list price thought mr azar note incent system often favor higher list price issu
believ administr look mechan medicar ff use pay part drug medicar pay
part b-cover drug base asp plu incentiv provid physician pick higher cost
drug compar cheaper altern sever concern rais overal price medicar part pay
drug lack price competit among drug similar health effect accord medpac
spend part cover drug increas y/i administr could look recommend
medpac includ improv asp data report appli penalti manufactur report
requir data modifi payment rate drug paid wac establish asp inflat rebat
permit privat vendor use tool formulari negoti price manufactur
access tool price negoti thought pbm mco sophist analyt tool resourc
captur real-tim data recommend lower cost altern effici manner particularli gener drug
manufactur updat drug price administr might focus use similar tool reduc drug
cost medicar part part program administr might also consid move drug paid
medicar part cover drug administ doctor offic part encourag activ cost
ensur adequ competit thought administr express concern pay-for-delay patent
settlement effect block gener competit number brand drug accord ftc studi
anticompetit deal result billion higher drug cost everi year fda commission scott gottlieb
also report ahip confer earlier year pay-for-delay scheme discourag cheaper version
expens biolog medicin come market
reduc pocket expens beneficiari thought believ administr focu
propos includ presid trump budget earlier year exampl one propos includ budget
focus point sale po rebat impli pass discount rebat negoti pbm
senior buy drug medicar part implement believ would result beneficiari pay less
out-of-pocket buy drug could potenti result higher premium insur adjust bid reflect
loss relev rebat
us tractor sale larg stabl april total us tractor sale unit april y/i larg
in-lin perform saw first three month year given y/i april perform drove
year-to-d sale horsepow tractor follow increas
impli year-to-d sale first four month year pull back april
follow increas march though slightli tougher comp smaller tractor mix
tractor jump put perspect tractor
tractor essenti flat total tractor inventori month/month
unit larg in-lin normal season
combin surpris upsid combin strong april sale unit follow drop
march drove ytd perform signific improv rel march
year-to-d basi
may wasd seen neutral corn slightli posit soybean us ag team us ag team also
publish quick insight may wasd today highlight us new crop corn end carri estim slightli
expect end carri number peg bu soybean front us new crop end carri
bu came expect driven increas export estim
headlin price previou day close unless otherwis note
receiv product pleas specifi credit suiss contact email call
compani mention price may
receiv product pleas specifi credit suiss contact email call
